
Go or no go? Lilly’s valuable diabetes contender
Tirzepatide heads for its first FDA approval and Enhertu eyes an earlier setting, as Verrica and Axsome keep their fingers crossed.

AACR 2022 – Novartis’s late Kras challenge to Amgen
Targeting Shp2 has disappointed, but Novartis shows that it might still make an impression in directly hitting Kras.

AACR 2022 – A weekend of updates yields few winners
The dour biotech market sees little to be impressed about in updates from Bicycle, Rubius, C4 and Zentalis, though well-received data gives Affimed a boost.

AACR 2022 – Biontech’s cell therapy effort bears fruit at last
But it’s still far too early to tell whether combining Car-T with an mRNA vaccine might improve response durability.

AACR 2022 – Affimed shows that 2021 was no fluke
An academic-sponsored trial gives Affimed’s NK cell engaging approach a huge endorsement.

Protagonist seeks an Ideal readout
A mid-stage hit with its ulcerative colitis project could see the company on course for blockbuster sales.